The use of monoclonal antibodies in autoimmunity treatment
Authors:
Open Access
- 31 December 2018
- journal article
- research article
- Published by Pirogov Russian National Research Medical University in Bulletin of Russian State Medical University
- No. 6,p. 150-154
Abstract
Recently, monoclonal antibodies (MA) have gained popularity as therapeutic agents for the treatment of autoimmune disorders. These antibodies target proinflammatory cytokines, as well as T and B cells potentially involved in the pathogenesis of such conditions. In the present work we attempt to give a systematic description of available therapeutic MA, highlight their key mechanisms of action and pinpoint their adverse effects. We believe that MA that are capable of recognizing and eliminating pathogenic T- and B-cell clones hold the most promise for medical application as biologics. Detection and identification of autoreactive lymphocyte clones is one of the most serious challenges of contemporary medicine.Keywords
Funding Information
- Ministry of Education and Science of the Russian Federation (RFMEFI60716X0158)
This publication has 30 references indexed in Scilit:
- A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacymAbs, 2014
- INTERLEUKIN-17 IS A NEW TARGET FOR ANTI-CYTOKINE THERAPY OF IMMUNE INFLAMMATORY RHEUMATIC DISEASESRheumatology Science and Practice, 2013
- Rituximab‐Induced T Cell Depletion in Patients With Rheumatoid Arthritis: Association With Clinical ResponseArthritis & Rheumatism, 2013
- Long-Term Remission of Diabetes in NOD Mice Is Induced by Nondepleting Anti-CD4 and Anti-CD8 AntibodiesDiabetes, 2012
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseasesNature Reviews Drug Discovery, 2012
- B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cellsJournal of Experimental Medicine, 2012
- Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicityCytotechnology, 2011
- IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+regulatory T cellsProceedings of the National Academy of Sciences, 2008
- B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritisRheumatology, 2005
- Role of tumour necrosis factor α in experimental arthritis: separate activity of interleukin 1β in chronicity and cartilage destructionAnnals of the Rheumatic Diseases, 1999